Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week.
Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of brain cancer. DAY101 is a Phase 2-ready RAF inhibitor that also shows strong potential for other pediatric and adult indications.
The company is co-founded by Chief Medical Officer Dr. Sam Blackman (who offered our May webinar) and Acting CEO Julie Grant from Canaan Partners.
You can read more here.
Please look for a planned CAC2 webinar later this year with representatives from Day One, OncoHeroes, and other companies devoting resources to developing drugs for children with cancer.
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (22)
- Collaborative Achievements (13)
- Community News (170)
- News Digest (130)
- Research Explained (10)
- Webinars (62)